Short answer
Protara Therapeutics, Inc. (TARA) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 text contains only an incorporation-by-reference disclaimer.
Protara Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 text contains only an incorporation-by-reference disclaimer
- No earnings figures, reporting-period results, or operating metrics disclosed in the provided text
Item EX-99.1 · Exhibit EX-99.1
- Cash, cash equivalents and investments $161.9M at June 30, 2026, expected to fund operations into 2028
- ADVANCED-2 BCG-unresponsive enrollment targeted for 4Q 2026, a key NMIBC registrational milestone
- ADVANCED-3 redesign broadens TARA-002 testing across BCG-naïve, BCG-exposed and papillary NMIBC populations
- STARBORN-1 interim data showed 83% clinical success among treated participants and 100% among evaluable patients
- Q2 net loss widened to $21.7M from $15.0M, while R&D expense rose to $17.0M from $10.8M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Protara Therapeutics, Inc. 8-K filings
Get the next TARA 8-K as it lands
Follow TARA for push alerts, or ask the research agent what this filing means.